EP3932949A4 - Anti-cd25 antibody and application thereof - Google Patents

Anti-cd25 antibody and application thereof Download PDF

Info

Publication number
EP3932949A4
EP3932949A4 EP20822215.8A EP20822215A EP3932949A4 EP 3932949 A4 EP3932949 A4 EP 3932949A4 EP 20822215 A EP20822215 A EP 20822215A EP 3932949 A4 EP3932949 A4 EP 3932949A4
Authority
EP
European Patent Office
Prior art keywords
antibody
application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20822215.8A
Other languages
German (de)
French (fr)
Other versions
EP3932949A1 (en
Inventor
Deyong SONG
Xiu LIU
Jing HAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Boan Biotechnology Co Ltd
Original Assignee
Shandong Boan Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Boan Biotechnology Co Ltd filed Critical Shandong Boan Biotechnology Co Ltd
Publication of EP3932949A1 publication Critical patent/EP3932949A1/en
Publication of EP3932949A4 publication Critical patent/EP3932949A4/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP20822215.8A 2019-06-10 2020-06-08 Anti-cd25 antibody and application thereof Pending EP3932949A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910495626 2019-06-10
CN201910495614 2019-06-10
PCT/CN2020/094919 WO2020248938A1 (en) 2019-06-10 2020-06-08 Anti-cd25 antibody and application thereof

Publications (2)

Publication Number Publication Date
EP3932949A1 EP3932949A1 (en) 2022-01-05
EP3932949A4 true EP3932949A4 (en) 2022-06-29

Family

ID=73780655

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20822215.8A Pending EP3932949A4 (en) 2019-06-10 2020-06-08 Anti-cd25 antibody and application thereof

Country Status (9)

Country Link
US (1) US20220195055A1 (en)
EP (1) EP3932949A4 (en)
JP (1) JP7245358B2 (en)
KR (1) KR20220007120A (en)
CN (1) CN113924316B (en)
AU (1) AU2020293160B2 (en)
BR (1) BR112021024826A2 (en)
CA (1) CA3135992C (en)
WO (1) WO2020248938A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024175020A1 (en) * 2023-02-22 2024-08-29 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-il2ra antibodies and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6521230B1 (en) * 1990-03-16 2003-02-18 Novartis Ag CD25 binding molecules
WO2004045512A2 (en) * 2002-11-15 2004-06-03 Genmab A/S Human monoclonal antibodies against cd25
WO2018167104A1 (en) * 2017-03-17 2018-09-20 Tusk Therapeutics Ltd Fc-optimized anti-cd25 for tumour specific cell depletion

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101340559B1 (en) * 2005-06-01 2013-12-11 암젠 리서치 (뮌헨) 게엠베하 Anti-IL2 antibodies
CN103571872B (en) 2012-08-09 2016-11-23 山东国际生物科技园发展有限公司 A kind of preparation method of the transgenic animal that can express people's antibody
US11117958B2 (en) * 2017-05-25 2021-09-14 Institute For Basic Science Anti-human interleukin-2 antibodies and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6521230B1 (en) * 1990-03-16 2003-02-18 Novartis Ag CD25 binding molecules
WO2004045512A2 (en) * 2002-11-15 2004-06-03 Genmab A/S Human monoclonal antibodies against cd25
WO2018167104A1 (en) * 2017-03-17 2018-09-20 Tusk Therapeutics Ltd Fc-optimized anti-cd25 for tumour specific cell depletion

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KENNETH W. WALKER ET AL: "Pharmacokinetic comparison of a diverse panel of non-targeting human antibodies as matched IgG1 and IgG2 isotypes in rodents and non-human primates", PLOS ONE, vol. 14, no. 5, 23 May 2019 (2019-05-23), pages e0217061, XP055722317, DOI: 10.1371/journal.pone.0217061 *
See also references of WO2020248938A1 *

Also Published As

Publication number Publication date
BR112021024826A2 (en) 2022-01-25
WO2020248938A1 (en) 2020-12-17
US20220195055A1 (en) 2022-06-23
EP3932949A1 (en) 2022-01-05
CN113924316A (en) 2022-01-11
JP2022527651A (en) 2022-06-02
CN113924316B (en) 2022-06-21
KR20220007120A (en) 2022-01-18
AU2020293160A1 (en) 2021-10-07
CA3135992A1 (en) 2020-12-17
JP7245358B2 (en) 2023-03-23
CA3135992C (en) 2024-02-13
AU2020293160B2 (en) 2024-07-25

Similar Documents

Publication Publication Date Title
EP3759143A4 (en) Anti-tigit antibodies and uses thereof
EP3904386A4 (en) Antibody and use thereof
EP3838289A4 (en) Anti-tigit antibody and uses thereof
EP3740224A4 (en) Anti-lilrb antibodies and uses thereof
EP3762030A4 (en) Anti-cd73 antibodies and uses thereof
EP3797124A4 (en) Anti-ror1 antibody and use thereof
EP3802612A4 (en) Anti-b7-h3 antibody and use thereof
EP3875484A4 (en) Cll1-targeting antibody and application thereof
EP3901175A4 (en) Anti-cd73 monoclonal antibody and application thereof
EP3918323A4 (en) Anti-gal3 antibodies and uses thereof
EP3907240A4 (en) Anti-tnfr2 antibody and use thereof
EP3891183A4 (en) Anti-claudin antibodies and uses thereof
EP3999545A4 (en) Anti-cd73 antibody and application thereof
EP3735427A4 (en) Anti-mct1 antibodies and uses thereof
EP4047019A4 (en) Anti-tslp antibody and uses thereof
EP4071172A4 (en) Anti-lilrb1 antibody and uses thereof
EP3997127A4 (en) Dll3-targeting antibodies and uses thereof
EP3790586A4 (en) Anti-dll3 antibodies and uses thereof
EP4043495A4 (en) Anti-human trop-2 antibody and application thereof
EP3904382A4 (en) Anti-il-23p19 antibody and uses thereof
EP3962954A4 (en) Anti-galectin-9 antibodies and uses thereof
EP4032904A4 (en) Anti-alpha-hemolysin antibody and use thereof
EP3768317A4 (en) Anti-il-27 antibodies and uses thereof
EP3962956A4 (en) Anti-hvem antibodies and use thereof
EP3894440A4 (en) Anti-il-27 antibodies and uses thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210928

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

A4 Supplementary search report drawn up and despatched

Effective date: 20220531

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/577 20060101ALI20220524BHEP

Ipc: A61P 35/00 20060101ALI20220524BHEP

Ipc: A61K 39/395 20060101ALI20220524BHEP

Ipc: C12N 15/63 20060101ALI20220524BHEP

Ipc: C12N 15/13 20060101ALI20220524BHEP

Ipc: C07K 16/28 20060101AFI20220524BHEP

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240318